SCHEMBL720290

SCHEMBL720290

CC(=O)c1nc(Cl)ccc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CA9 Q16790 1/20 0.49
BRD4 O60885 1/20 0.47
MAOB P27338 2/20 0.47
MRGPRX4 Q96LA9 1/20 0.45
PTGER1 P34995 7/20 0.44
GAA P10253 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM3 P20309 1/20 0.44
CLCN2 P51788 1/20 0.44
HPGD P15428 1/20 0.43
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7845570 0.86 GAA (0.48) SMN1; SMN2BRD4PTGER1GAACHRM4
SCHEMBL27852272 0.86 SMN1; SMN2 (0.52) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL716542 0.83 MAPT (0.50) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL20616566 0.82 SMN1; SMN2 (0.49) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL4691988 0.78 LTA4H (0.55) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL29836285 0.78 LTA4H (0.55) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL30858374 0.77 SMN1; SMN2 (0.56) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL28848218 0.77 MAPT (0.46) MAPTSMN1; SMN2TDP1L3MBTL1MAOB
SCHEMBL30522860 0.77 MAPT (0.46) MAPTSMN1; SMN2TDP1L3MBTL1MAOB
SCHEMBL8625960 0.77 HTT (0.49) MAPTSMN1; SMN2L3MBTL1CA9MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MAPT 4533/4885CYP2C9 896/4885CYP2C19 946/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MAPT 4533/4885CYP2C9 896/4885CYP2C19 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.